Log inTry free

Savara (SVRA) stock

Market cap $1.0B

$5.05
-2.23%

Market closed. Prices as of Thursday's close.

Quality Score
-1
Poor
In its industry
#58of 89
Pharma
NextNov 22, 2026 · In 51 days…three-month extension of the Prescription Drug User Fee Act ("PDUFA") target action date to November 22, 2026…FDA decision date · 10-Q, Aug 11
Cash$173M, about 6 quarters at the last year's spendingOn Jun 30

Follow SVRA's trial news. Pro members can get an alert when Savara files news, and see its trials, share raises, and its CEO's filings.

Get an optional alert when SVRA files news on its trialsFree for 24 hours. No account needed.
Cash$173M, about 6 quarters at the last year's spendingOn Jun 30
Pipeline and cash

What's next for SVRA, and how long its cash lasts

From Savara’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.

Next step the company has named

Nov 22In 51 days…during their review constituted a major amendment to the BLA, resulting in a three-month extension of the Prescription Drug User Fee Act ("PDUFA") target action date to November 22, 2026.FDA decision date · 10-Q, Aug 11

What it means: the date by which the FDA has said it aims to decide on the company’s application. The FDA can decide earlier, or extend the date.

A trial underway
Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).Phase 3 · Recruiting · 5 people · main data estimated Jun 2027 · NCT06431776

1 more trial, 21 filings, for Pro members.

Cash runway Jun 30 balance sheet

About 6 quarters

$173M in cash and short-term investments, at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money.

For Pro members: whether the cash lasts past the FDA date, the cash used each quarter, and the math.

Dilution on the horizon

  • Shelf registration (S-3, filed May 9, 2024)
  • At-the-market share sales program (S-3, filed May 9, 2024)

A shelf lets a company sell shares later; an at-the-market program sells them into the market over time. Neither is a sale by itself.

For Pro members: 2 raises and their amounts, and the share count against a year ago.

Insiders

CFO David L Lowrance sold 394,528 shares on Jun 22.

From their own Form 4 filings: buys and sales in the market, not awards or shares withheld for tax.

Get an optional alert when Matthew Pauls buys or sells

For Pro members: every trade, and Matthew Pauls’s 4 filings and quotes.

Get an optional alert before SVRA's FDA date

Free for 24 hours. No account needed. Then keep going with a free account.

See every upcoming FDA date →

Biotech dates

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.

DateStockDrug

8 more FDA dates and 107 trial data dates in the next 60 days. Pro members see every one, with the cash against its date and an optional alert before it. Get in free →

Quality Score

Why SVRA scores -1

PoorChoppy, 1 of 14 checks firingWhat the Quality Score means

Poor is below 0. Average starts at 6, Above Average at 11, Excellent at 15, and Exceptional at 20.

  • +1Chart checks 1 of 14 firing right now, one point each
  • +1Long-term trend below a rising 200-⁠day average
  • Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
  • Dilution subtractsNew shares over the year: -1 at 10% more, -2 at 25% more.
  • Cash flow subtracts-1 when free cash flow over the last four quarters is negative.

No effect today: Run-up, Size, Growth, Volatility, Persistence, and News.

What every line is worth, and the reason behind it, on SVRA and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 1:33 AM ET, at least 15 minutes behind. How we rank stocks.

What's next

Expected to report Wed Nov 11, after the close

What would turn SVRA's score around: 7 things, for Pro members

Alert me when SVRA's Quality Score turns up

Free for 24 hours. No account needed. Then keep going with a free account.

Pro

Here is what Pro members see.

Every stock gets a card like this one, and a page with its price in real time, every line of its score, the chart, and its filings.

A Pro member's scanner card for AMD: the Quality Score badge, the rank in the scan and in its industry, the chart checks bar, three plain lines on its strength, notable holders, and early signs, and pills for size, volume, RSI, and short interest
A card on the scanner, shown on AMD
A Pro member's stock page for AMD: the Quality Score with its rank, the checks firing, and the reason behind it, the live price, and the chart
A stock page
The scanner a Pro member sees: every stock as a card with its Quality Score, rank, and chart checks bar, and the watchlist
The scanner
The 14 checks

SVRA has 1 of 14 checks firing

One per group is shown here.

Trend1 of 5 shown
MA FAN21 EMAW.EMAHH/HL52W HI

Averages stacked in order, price near its high.

Volume1 of 3 shown
VOLVDUU/D VOL

Heavy volume on the run, quiet volume at rest.

Tight range1 of 3 shown
ATR SQZSQUEEZENR7

The daily range is tight against its own recent history.

Buying1 of 3 shown
OBV+CLOSE HISPRING

Closes near the high, and buyers step in on dips.

The other 10 checks on SVRA, and all 14 on every stock.Get in free →

Also on the chart

Not scored

Shown for reference. None of these counts toward the Quality Score: in our tests on 20 years of daily prices, none of them improved it.

  • RSI 1441.7

    Above 30, below 50.

  • MACD (12, 26, 9)Below signal

    Crossed below its signal line 6 sessions ago.

  • 50-day average$5.40

    The price is 6.6% below it.

  • 200-day average$5.53

    The price is 8.8% below it. The 50-day is below the 200-day, since Sep 11.

  • ADX 1414.8

    Under 25, with +DI below -DI.

  • Support$4.83

    Swing low from Apr 29, 4.2% below the price.

  • Resistance$5.42

    Swing high from May 14, 7.3% above the price.

  • Bollinger Bands (20, 2)Inside

    The bands run from $4.93 to $5.57.

  • Volume1.3x

    Against its 20-day average, for the time of day.

Its industry

How SVRA ranks in Pharma

SVRA is #58 of 89 by Quality Score. The top three are shown with their scores, and more by name.

More in Pharma, on the Healthcare page

Earnings

When does SVRA report earnings, and what happens after?

Expected to report Wed Nov 11, after the close (in 40 days). Not yet confirmed by the company.

Filings

Who is trading SVRA

SVRA insider trades

One insider sold $2.2M across 1 filing in the last 6 months. No open-⁠market buys on record. The newest:

SellDavid L Lowrance$2.2MChief Financial Officerat $5.68 on Jun 22, filed Jun 22

An insider has two business days to file a Form 4, so the trade is already days old when it becomes public. Shown as filed, with no delay.

The company

About Savara

Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).

70 employeesAustin, TXsavarapharma.com

Pro

Every line of the score, on every stock.

  • Real-time prices, no delay
  • Every line of SVRA's score, with the points and the reason
  • All 14 checks on SVRA and on all 2,958 stocks
  • Every stock ranked, with the chart
  • Every filing, and optional alerts on SVRA
BreakawayJun 22David L Lowrance sold SVRA$2.2M at $5.68, filed Jun 22

What a filing on SVRA would have sent. Alerts are optional.

See all 14 checks on SVRAFree for 24 hours. No account needed. Then keep going with a free account.
Questions

Straight Answers.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, trial included, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Where does the data come from?

Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.

Do I need an account?

Not for the first 24 hours. Tap any green button and you're in, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.

Is this investment advice?

No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes. Filings are shown as filed, because a disclosure is already days or weeks old when it becomes public. Earnings dates and past reactions are settled sessions.